Blood, Cerebrospinal Fluid, Plasma, Trigeminal Neuralgia
Conditions
Brief summary
Trigeminal neuralgia is a type of neuropathic pain that brings great physical and psychological pressure to patients. Chronic pain can cause changes in the composition of central and peripheral body fluids, and these changes may be useful for the prediction and treatment of pain. In this study, the whole blood of patients with trigeminal neuralgia and non-chronic pain was collected, and transcriptome sequencing (RNA-seq) was performed to determine the peripheral transcriptome changes of trigeminal neuralgia (TN) patients. And compare the expression of neuropeptide Y (NPY) in plasma and cerebrospinal fluid of TN and non-chronic pain patients.
Detailed description
Trigeminal neuralgia is a kind of paroxysmal, knife-cutting, stubborn and severe pain in the facial distribution area of the trigeminal nerve caused by slight stimulation, which brings a great physical and psychological burden to the patient. Chronic pain can cause changes in the composition of central and peripheral body fluids, and these changes are very useful for the prediction and treatment of pain. In this study, the whole blood of patients with trigeminal neuralgia and non-chronic pain was collected for transcriptome sequencing (RNA-seq) sequencing. The results of transcriptome sequencing can derive the differentially expressed genes in the whole blood of TN patients and the pathways enriched by differentially expressed genes. At the same time, NPY (Neuropeptide y) plays an important role in head and face pain. We will also verify the difference in NPY expression in the cerebrospinal fluid and plasma of TN and non-chronic pain patients, and the correlation between NPY expression and pain.
Interventions
None listed
Sponsors
Peking University People's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Inclusion criteria
1. Patients with primary trigeminal neuralgia receive trigeminal nerve microvascular decompression, and healthy people without a history of chronic pain or patients with facial nerve palsy without chronic pain receive facial nerve decompression as a control; 2. Age from 30 to 60 years old 3. Complete white blood cell count: 4.8\ 11.0x109/L
Exclusion criteria
1. Patients with co-infection and tumor 2. Patients with craniocerebral disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Score (VAS) | The VAS score is tested before surgery in the preoperative preparation room | VAS score is a pain score |
| Differentially expressed genes | blood will be taken from two groups of patients before operation | Transcriptome analysis of whole blood cell from patients with trigeminal neuralgia or non-chronic pain reveals differential gene expression between the two groups |
| Differentially expressed genes (DEGs) enrichment pathway | blood will be taken from two groups of patients before operation | We will perform pathway enrichment analysis on the DEGs obtained by transcriptome analysis of the whole blood cell from patients with trigeminal neuralgia or non-chronic pain. |
| Neuropeptide y expression | Cerebrospinal fluid will be collected during the surgery; Plasma will be collected before the surgery in the preoperative preparation room. | We detect neuropeptide Y levels in the cerebrospinal fluid and plasma of patients with trigeminal neuralgia and non-chronic pain |
Contacts
Primary ContactYi Feng, MD,PhD
Outcome results
None listed